

References

1. Thies, W. & Bleiler, L. 2012 Alzheimer's disease facts and figures Alzheimer's Association *. Alzheimer's & Dementia 8, 131-168 (2012).
2. CDC. Caregiving for Person with Alzheimer's Disease or a related Dementia | Alzheimer's Disease and Healthy Aging | CDC. <https://www.cdc.gov/aging/caregiving/alzheimer.htm> (2019).
3. Prince, M. et al. The global prevalence of dementia: A systematic review and meta-analysis. Alzheimer's and Dementia 9, 63-75.e2 (2013).
4. Alzheimer's Association. 2020 Alzheimer's disease facts and figures. Alzheimer's & Dementia 16, 391-460 (2020).
5. Murden, R. A. The Diagnosis of Alzheimer's Disease. Advances in Experimental Medicine and Biology 282, 59-64 (1990).
6. Jack, C. R. et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539 (2016).
7. Lee, J. C., Kim, S. J., Hong, S. & Kim, Y. S. Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers. Experimental & Molecular Medicine 2019 51:5 51, 1-10 (2019).
8. Neugroschl, J. & Wang, S. Alzheimer's Disease: Diagnosis and Treatment Across the Spectrum of Disease Severity. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78, 596-612 (2011).
9. Breijyeh, Z. & Karaman, R. Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules (Basel, Switzerland) vol. 25 5789 (2020).
10. Jack, C. R. et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia 14, 535-562 (2018).
11. Mirra, S. S. et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486 (1991).
12. Khan, T. K. et al. PKC ϵ Deficits in Alzheimer's Disease Brains and Skin Fibroblasts. Journal of Alzheimer's Disease 43, 491-509 (2015).
13. Khan, T. K., Nelson, T. J., Verma, V. A., Wender, P. A. & Alkon, D. L. A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses A β -induced biomarker abnormality on cultured fibroblasts. Neurobiology of Disease 34, 332-339 (2009).
14. Alkon, D. L., Sun, M. K. & Nelson, T. J. PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. Trends in Pharmacological Sciences 28, 51-60 (2007).
15. Choi, D. S. et al. PKC ϵ increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc Natl Acad Sci U S A 103, 8215-8220 (2006).
16. Nelson, T. J., Cui, C., Luo, Y. & Alkon, D. L. Reduction of β -amyloid levels by novel protein kinase C activators. Journal of Biological Chemistry 284, 34514-34521 (2009).
17. Etcheberrigaray, R. et al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci U S A 101, 11141-11146 (2004).
18. Takashima, A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. Journal of Alzheimer's Disease 9, 309-317 (2006).
19. Chirila, F. V., Khan, T. K. & Alkon, D. L. Spatiotemporal Complexity of Fibroblast Networks Screens for Alzheimer's Disease. Journal of Alzheimer's Disease 33, 165-176 (2013).
20. Khan, T. K. & Alkon, D. L. Peripheral Biomarkers of Alzheimer's Disease. Journal of Alzheimer's Disease 44, 729-744 (2015).

This test was developed, and its performance characteristics determined by NeuroDiagnostics, Inc., dba Synaps Dx. It has not been cleared or approved by the US Food and Drug Administration. NeuroDiagnostics Inc. is registered under the Clinical Laboratory Improvement Amendments (CLIA) as an accredited laboratory to perform high complexity clinical testing. The test is indicated for patients diagnosed with dementia. Test results should be interpreted in conjunction with other laboratory and clinical data available to the clinician. All rights reserved.



DISCERN[™]
Simple. Accurate. Peace of Mind.

SYNAPS DX

12358 PARKLAWN DRIVE, SUITE 230
ROCKVILLE, MD 20852

WWW.DISCERNTEST.COM